Propranolol as First-line Treatment of Head and Neck Hemangiomas

Laboratory studies have suggested that adrenergic blockers may inhibit the proliferation and migration of cancer cells, but epidemiological evidence of their effect on cancer incidence has proven inconsistent. We therefore conducted a case-control study using the Clinical Practice Research Datalink to assess the effect of adrenergic blockers on the incidence of prostate, lung, bowel and breast cancers. From among patients aged 18 years or older who contributed at least 2 years of prospectively gathered data between 1 January 1987 and 31 December 2012, we selected incident cases of relevant cancers and controls, frequency matched 10 : 1 by age. Logistic regression was used to adjust effect estimates for age, sex, smoking, alcohol use, and a number of potentially confounding comorbidities and coprescriptions. A total of 18 968 colorectal, 19 082 lung, 21 608 prostate and 29 109 breast cancers were identified. We found no evidence of a protective effect of adrenergic blockade in lung and prostate cancers and found a slightly increased risk for colorectal and breast cancers in users. This was largely explained by the effects of confounding in multivariate analyses, with final odds ratio estimates for lung, colorectal, breast and prostate cancers of 0.99 [95% confidence interval (0.96-1.04)], 1.14 (1.09-1.18), 1.10 (1.06-1.14), and 1.01 (0.98-1.05), respectively, for β-blocker exposure, and final odds ratio estimates for lung, colorectal and breast cancer of 1.03 (0.97-1.09), 1.13 (1.07-1.20), and 1.08 (1.00-1.17), respectively, for α-blocker exposure. We found no evidence to suggest that adrenergic blocker use prevents common cancers. Indeed, we found a slightly increased risk for colorectal and breast cancers, which may reflect residual confounding.

show abstract

“…Furthermore, β-blockade has proven efficacy in the treatment of infantile haemangiomas (Fuchsmann et al, 2011;Xu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Adrenergic blockers and the risk for common solid cancers: a case–control study

Numbere¹,

Fleming²,

Walker³

et al. 2017

European Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Fuschman et al treated IH with propanolol in hemangiomas of various locations, and resulted in involution within 2 -14 days [9].…”

Section: Discussionmentioning

confidence: 99%

Infantile Hemangioendothelioma of the Parotid Gland

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Esto se debería al componente profundo del hemangioma, al retiro precoz del medicamento o prolongación de la fase proliferativa de esta lesión benigna 25 .…”

Section: Discussionunclassified

Hemangioma subglótico tratado con propranolol: Una nueva alternativa terapéutica. Caso clínico

2013

Rev. chil. pediatr.

View full text Add to dashboard Cite

Propranolol for the treatment of subglotic hemangioma-A new therapeutic alternativeInfantile Subglottic Hemangiomas (ISH) are rare and potentially fatal. Many treatments have been described for this condition. Propranolol is a new therapeutic alternative, with successful results in skin and airway infantile hemangiomas. Case study: The case of an infant with ISH and 90% blockage of his airway is presented. The patient underwent a tracheostomy procedure and then treated with oral propranolol, showing a good response after a month of treatment, presenting 10% obstruction and consequently, ending the tracheostomy early. Conclusion: The discovery of the effect of propranolol in the ISH has revolutionized the management of this condition, displacing steroids and surgery as first-line treatments. This study discusses the current ISH management. RESUMENLos hemangiomas infantiles subglóticos (HIS) son poco frecuentes y potencialmente mortales. Muchos tratamientos se han descrito para los HIS. El propranolol es una nueva alternativa terapéutica, con resultados exitosos en hemangiomas infantiles de piel y de vía áerea. Caso clínico: Se reporta el manejo de un lactante con HIS que presentaba una obstrucción del 90% de su vía aérea, que debió ser traqueostomizado, luego se inicio propranolol oral, presentando una muy buena respuesta al mes de tratamiento, con 10% de obstrucción, retirando traqueostomía precozmente. Conclusión: El descubrimiento del efecto del propranolol en los HIS ha revolucionado su manejo, desplazando a los corticoides y a la cirugía como primera línea de tratamiento. En el presente reporte se discute el manejo actual de los HIS.

show abstract

Propranolol as First-line Treatment of Head and Neck Hemangiomas

Cited by 81 publications

References 20 publications

Adrenergic blockers and the risk for common solid cancers: a case–control study

Adrenergic blockers and the risk for common solid cancers: a case–control study

Infantile Hemangioendothelioma of the Parotid Gland

Hemangioma subglótico tratado con propranolol: Una nueva alternativa terapéutica. Caso clínico

Contact Info

Product

Resources

About